NTUS Insider Trading Activity and SEC Form 4 Filings
NTUS insider trading summary
No open-market insider purchases or sales of Natus Medical Inc (NTUS) have been reported on SEC Form 4 in the past 12 months.
Latest NTUS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 9, 2021 | Dong Chune Christopher Chung | Chief Medical Officer | Sell | $272K (11,787 @ $23.08) |
| Jun 11, 2021 | Ilan Daskal | Director | Sell | $69K (2,500 @ $27.46) |
| Jun 11, 2021 | Alice D. Schroeder | Director | Sell | $81K (2,934 @ $27.49) |
| Jun 1, 2021 | Dong Chune Christopher Chung | VP of Medical Affairs | Sell | $344K (12,500 @ $27.55) |
| May 28, 2021 | Dong Chune Christopher Chung | VP of Medical Affairs | Sell | $22K (808 @ $26.90) |
| May 27, 2021 | Dong Chune Christopher Chung | VP of Medical Affairs | Sell | $284K (10,467 @ $27.10) |
| May 25, 2021 | Dong Chune Christopher Chung | VP of Medical Affairs | Sell | $259K (9,435 @ $27.41) |
| May 24, 2021 | Dong Chune Christopher Chung | VP of Medical Affairs | Sell | $542K (20,000 @ $27.11) |
| May 20, 2021 | Dong Chune Christopher Chung | VP of Medical Affairs | Sell | $251K (9,290 @ $27.00) |
| May 19, 2021 | Dong Chune Christopher Chung | VP of Medical Affairs | Sell | $169K (6,367 @ $26.54) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.